Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.
Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.
复制标题
DOI：
10.1097/qai.0000000000000478
复制
发表时间：
2015-04-01
期刊：
影响因子：
--
通讯作者：
McComsey GA
中科院分区：
文献类型：
--
作者：
Funderburg NT;Jiang Y;Debanne SM;Labbato D;Juchnowski S;Ferrari B;Clagett B;Robinson J;Lederman MM;McComsey GA
尽管抑制抗逆转录病毒治疗（ART），增加的免疫激活水平在hiv感染者中持续存在。他汀类药物具有抗炎作用，并可能降低HIV疾病的免疫激活。SATURN-HIV是一项随机、双盲、安慰剂对照试验，评估瑞舒伐他汀（10mg/d）对接受抗逆转录病毒治疗的患者心血管风险标志物和免疫激活的影响。通过CD38、HLA-DR和PD1的表达来检测T细胞的活化。通过可溶性标记物（sCD14和sCD163）、单核细胞亚群计数和组织因子（TF）表达来测定单核细胞活化。还测量了全身和血管炎症及凝血指标。与安慰剂相比，瑞舒伐他汀在48周后降低了sCD14 （- 10.4% vs 0.5%p=0.006）、Lp-PLA2 （- 12.2% vs - 1.7% p=0.0007）和IP-10 （- 27.5 vs - 8.2%, p=0.03）水平。瑞舒伐他汀组TF+巡逻（CD14DimCD16+）单核细胞的比例也比安慰剂组（- 18.8%,p=0.005）降低（- 41.6%）。两臂间活化的（CD38+HLA-DR+） T细胞的比例也有较大的下降（CD4+细胞为- 38.1%对- 17.8%,p=0.009， CD8+细胞为- 44.8%对- 27.4%,p=0.003）。48周的瑞舒伐他汀治疗显著降低了接受art治疗的受试者的炎症、淋巴细胞和单核细胞活化的几种标志物。
Despite suppressive antiretroviral therapy (ART), increased levels of immune activation persist in HIV-infected subjects. Statins have anti-inflammatory effects and may reduce immune activation in HIV disease. SATURN-HIV is a randomized, double-blind, placebo-controlled trial assessing the effect of rosuvastatin (10mg/daily) on markers of cardiovascular risk and immune activation in ART-treated patients. T cell activation was measured by expression of CD38, HLA-DR, and PD1. Monocyte activation was measured with soluble markers (sCD14 and sCD163) and by enumeration of monocyte subpopulations and tissue factor (TF) expression. Markers of systemic and vascular inflammation and coagulation were also measured. SATURN-HIV is registered on clinicaltrials.gov, Identifier: NCT01218802 Rosuvastatin, compared to placebo, reduced sCD14 (−10.4% vs 0.5%p=0.006), Lp-PLA2 (−12.2% vs −1.7% p=0.0007), and IP-10 (−27.5 vs −8.2%, p=0.03) levels after 48 weeks. The proportion of TF+ patrolling (CD14DimCD16+) monocytes was also reduced by rosuvastatin (−41.6%) compared to the placebo (−18.8%, p=0.005). There was also a greater decrease in the proportions of activated (CD38+HLA-DR+) T cells between the arms (−38.1% vs −17.8%, p=0.009 for CD4+ cells and −44.8% vs −27.4%, p=0.003 for CD8+ cells). 48 weeks of rosuvastatin treatment reduced significantly several markers of inflammation and lymphocyte and monocyte activation in ART-treated subjects.